Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011, Article ID 201787, 7 pages
http://dx.doi.org/10.1155/2011/201787
Review Article

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis

Division of Immunology and Rheumatology, Departments of Dermatology and Medicine, Stanford University School of Medicine, Palo Alto VA Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304, USA

Received 2 June 2011; Accepted 17 August 2011

Academic Editor: Virginia D. Steen

Copyright © 2011 Kait Arefiev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. H. Korn, “Pathogenesis of systemic sclerosis,” in Arthritis and Allied Conditions, W. J. Koopman, Ed., pp. 1643–1654, Williams & Wilkins, Baltimore, Md, USA, 2001. View at Google Scholar
  2. F. M. Wigley, “Vascular disease in scleroderma,” Clinical Reviews in Allergy and Immunology, vol. 36, no. 2-3, pp. 150–175, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. Ferri, G. Valentini, F. Cozzi et al., “Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients,” Medicine, vol. 81, no. 2, pp. 139–153, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. L. K. Hummers and F. M. Wigley, “Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma,” Rheumatic Disease Clinics of North America, vol. 29, no. 2, pp. 293–313, 2003. View at Google Scholar · View at Scopus
  5. L. Chung and D. Fiorentino, “Digital ulcers in patients with systemic sclerosis,” Autoimmunity Reviews, vol. 5, no. 2, pp. 125–128, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. V. Steen, C. P. Denton, J. E. Pope, and M. Matucci-Cerinic, “Digital ulcers: overt vascular disease in systemic sclerosis,” Rheumatology, vol. 48, supplement 3, pp. 19–24, 2009. View at Google Scholar · View at Scopus
  7. C. Denton and J. Korn, “Digital ulceration and critical digital ischemia in scleroderma,” Journal of the Scleroderma Clinical Trials Consortium, vol. 1, no. 2, pp. 12–16, 2003. View at Google Scholar
  8. F. Galluccio and M. Matucci-Cerinic, “Two faces of the same coin: raynaud phenomenon and digital ulcers in systemic sclerosis,” Autoimmunity Reviews, vol. 10, no. 5, pp. 241–243, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. E. Thompson, B. Shea, V. Welch, D. Fenlon, and J. E. Pope, “Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis,” Arthritis and Rheumatism, vol. 44, no. 8, pp. 1841–1847, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. D. B. Badesch, V. F. Tapson, M. D. McGoon et al., “Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial,” Annals of Internal Medicine, vol. 132, no. 6, pp. 425–434, 2000. View at Google Scholar · View at Scopus
  11. L. Chung and D. Fiorentino, “A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis,” Journal of the American Academy of Dermatology, vol. 54, no. 5, pp. 880–882, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. F. M. Wigley, J. R. Seibold, R. A. Wise, D. A. McCloskey, and W. P. Dole, “Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic slcerosis,” Journal of Rheumatology, vol. 19, no. 9, pp. 1407–1414, 1992. View at Google Scholar · View at Scopus
  13. J. Gore and R. Silver, “Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 64, no. 9, article 1387, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. C. S. Brueckner, M. O. Becker, T. Kroencke et al., “Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study,” Annals of the Rheumatic Diseases, vol. 69, no. 8, pp. 1475–1478, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. P. D. Shenoy, S. Kumar, L. K. Jha et al., “Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial,” Rheumatology, vol. 49, no. 12, Article ID keq291, pp. 2420–2428, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. P. M. Campbell and E. C. LeRoy, “Pathogenesis of systemic sclerosis: a vascular hypothesis,” Seminars in Arthritis and Rheumatism, vol. 4, no. 4, pp. 351–368, 1975. View at Publisher · View at Google Scholar · View at Scopus
  17. R. J. Gryglewski, R. M. Botting, and J. R. Vane, “Mediators produced by the endothelial cell,” Hypertension, vol. 12, no. 6, pp. 530–548, 1988. View at Google Scholar · View at Scopus
  18. S. Kourembanas, L. P. McQuillan, G. K. Leung, and D. V. Faller, “Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia,” The Journal of Clinical Investigation, vol. 92, no. 1, pp. 99–104, 1993. View at Google Scholar · View at Scopus
  19. T. Yamamoto, I. Katayama, and K. Nishioka, “Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis,” Journal of Rheumatology, vol. 25, no. 2, pp. 314–317, 1998. View at Google Scholar · View at Scopus
  20. T. R. Katsumoto, M. L. Whitfield, and M. K. Connolly, “The pathogenesis of systemic sclerosis,” Annual Review of Pathology, vol. 6, pp. 509–537, 2011. View at Publisher · View at Google Scholar · View at PubMed
  21. M. Yanagisawa, A. Inoue, Y. Takuwa, Y. Mitsui, M. Kobayashi, and T. Masaki, “The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling,” Journal of Cardiovascular Pharmacology, vol. 13, supplement 5, pp. S13–S17, 1989. View at Google Scholar
  22. A. Inoue, M. Yanagisawa, S. Kimura et al., “The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 8, pp. 2863–2867, 1989. View at Google Scholar · View at Scopus
  23. G. M. Rubanyi and M. A. Polokoff, “Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology,” Pharmacological Reviews, vol. 46, no. 3, pp. 325–415, 1994. View at Google Scholar · View at Scopus
  24. M. D. Mayes, “Endothelin and endothelin receptor antagonists in systemic rheumatic disease,” Arthritis and Rheumatism, vol. 48, no. 5, pp. 1190–1199, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. L. Biondi, B. Marasini, C. Bassani, and A. Agostoni, “Increased plasma endothelin levels in patients with Raynaud's phenomenon,” The New England Journal of Medicine, vol. 324, no. 16, pp. 1139–1140, 1991. View at Google Scholar · View at Scopus
  26. K. Yamane, T. Miyauchi, N. Suzuki et al., “Significance of plasma endothelin-1 levels in patients with systemic sclerosis,” Journal of Rheumatology, vol. 19, no. 10, pp. 1566–1571, 1992. View at Google Scholar · View at Scopus
  27. M. R. Zamora, R. F. O'Brien, R. B. Rutherford, and J. V. Weil, “Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon,” The Lancet, vol. 336, no. 8724, pp. 1144–1147, 1990. View at Google Scholar · View at Scopus
  28. M. B. Kahaleh, “Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action,” Arthritis and Rheumatism, vol. 34, no. 8, pp. 978–983, 1991. View at Google Scholar · View at Scopus
  29. V. Richard, V. Solans, J. Favre et al., “Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1,” Fundamental and Clinical Pharmacology, vol. 22, no. 6, pp. 649–655, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. K. W. Frommer and U. Müller-Ladner, “Expression and function of ETA and ETB receptors in SSc,” Rheumatology, vol. 47, supplement 5, pp. 27–28, 2008. View at Google Scholar · View at Scopus
  31. M. Jain and J. Varga, “Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers,” Expert Opinion on Pharmacotherapy, vol. 7, no. 11, pp. 1487–1501, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. R. N. Channick, G. Simonneau, O. Sitbon et al., “Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study,” The Lancet, vol. 358, no. 9288, pp. 1119–1123, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. L. J. Rubin, D. B. Badesch, R. J. Barst et al., “Bosentan therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 346, no. 12, pp. 896–903, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. R. J. Oudiz, N. Galiè, H. Olschewski et al., “Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 54, no. 21, pp. 1971–1981, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. X. Shiwen, A. Leask, D. J. Abraham, and C. Fonseca, “Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma,” European Journal of Clinical Investigation, vol. 39, supplement 2, pp. 19–26, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. Humbert and J. Cabane, “Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan,” Rheumatology, vol. 42, no. 1, pp. 191–193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Tillon, F. Hervé, D. Chevallier, J. F. Muir, H. Levesque, and I. Marie, “Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy,” British Journal of Dermatology, vol. 154, no. 5, pp. 1000–1002, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. R. Roldan, G. Morote, M. D. C. Castro, M. D. Miranda, J. C. Moreno, and E. Collantes, “Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children,” Journal of Rheumatology, vol. 33, no. 12, pp. 2538–2540, 2006. View at Google Scholar · View at Scopus
  39. M. Chamaillard, I. Heliot-Hosten, J. Constans, and A. Taïeb, “Bosentan as a rescue therapy in scleroderma refractory digital ulcers,” Archives of Dermatology, vol. 143, no. 1, pp. 125–126, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. M. E. G. Ferreira and M. A. Scheinberg, “Successful treatment with bosentan of non-digital skin ulcers in severe scleroderma,” Annals of the Rheumatic Diseases, vol. 67, no. 12, pp. 1784–1785, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. P. Gholam, T. Sehr, A. Enk, and M. Hartmann, “Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan),” Dermatology, vol. 219, no. 2, pp. 171–173, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. J. H. Korn, M. Mayes, M. Matucci Cerinic et al., “Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 3985–3993, 2004. View at Publisher · View at Google Scholar · View at PubMed
  43. N. Selenko-Gebauer, N. Duschek, G. Minimair, G. Stingl, and F. Karlhofer, “Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan,” Rheumatology, vol. 45, supplement 3, pp. 45–48, 2006. View at Publisher · View at Google Scholar · View at PubMed
  44. P. García de la Peña-Lefebre, S. Rodríguez Rubio, M. Valero Expósito et al., “Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients,” Rheumatology, vol. 47, no. 4, pp. 464–466, 2008. View at Publisher · View at Google Scholar · View at PubMed
  45. M. Funauchi, K. Kishimoto, H. Shimazu et al., “Effects of bosentan on the skin lesions: an observational study from a single center in Japan,” Rheumatology International, vol. 29, no. 7, pp. 769–775, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. N. Tsifetaki, V. Botzoris, Y. Alamanos, E. Argyriou, A. Zioga, and A. A. Drosos, “Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study,” Journal of Rheumatology, vol. 36, no. 7, pp. 1550–1551, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. V. A. Nguyen, K. Eisendle, I. Gruber, B. Hugl, D. Reider, and N. Reider, “Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study,” Rheumatology, vol. 49, no. 3, pp. 583–587, 2009. View at Publisher · View at Google Scholar · View at PubMed
  48. A. Kuhn, M. Haust, V. Ruland et al., “Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial,” Rheumatology, vol. 49, no. 7, Article ID keq077, pp. 1336–1345, 2010. View at Publisher · View at Google Scholar · View at PubMed
  49. N. Giordano, L. Puccetti, P. Papakostas et al., “Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 4, pp. 1185–1194, 2010. View at Google Scholar
  50. M. Matucci-Cerinic, C. P. Denton, D. E. Furst et al., “Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 32–38, 2011. View at Publisher · View at Google Scholar · View at PubMed
  51. V. K. Shanmugam, P. Price, C. E. Attinger, and V. D. Steen, “Lower extremity ulcers in systemic sclerosis: features and response to therapy,” International Journal of Rheumatology, vol. 2010, Article ID 747946, 8 pages, 2010. View at Publisher · View at Google Scholar · View at PubMed